Asia Spotlight: Improve Quality Or You're Out, Says China FDA Commissioner
In a rare public speech, China FDA Commissioner Bi Jingquan calls for improved drug quality and an ecosystem to reward high-quality medicines, highlighting the agency’s drive to step up enforcement amid another recent scandal that has revealed broad quality problems.
You may also be interested in...
Amid aftermath of latest vaccine scandal, top officials including China’s drug reform flagbearer are forced to resign, sending shock waves across the industry.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.